<DOC>
	<DOC>NCT00532571</DOC>
	<brief_summary>To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).</brief_summary>
	<brief_title>Effects of Coenzyme Q10 in PSP and CBD</brief_title>
	<detailed_description />
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years Age &gt; 40 Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit. Patients agreeable to participate in the study. Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit. Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs. History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant. Previous use of coenzyme Q10 within 60 days of the baseline visit.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>CoQ10</keyword>
	<keyword>PSP</keyword>
	<keyword>CBD</keyword>
</DOC>